CHILD-BRIGHT Network and Ehave Start Enrollment for Cognitive Rehabilitation Trial for Children with ADHD, Autism, and Congenital Heart Disease

By June 28, 2018 MegaTeam, Press Releases

The CHILD-BRIGHT Mega Team game is an innovative video game-based cognitive intervention that aims to improve executive functions in children with brain-based developmental disabilities.

The CHILD-BRIGHT Network, a Canadian patient-oriented research network focused on pediatric brain-based developmental disorders, and Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the start of enrollment for the CHILD-BRIGHT Mega Team research project trial, a Canadian-developed video game-based cognitive intervention that aims to improve executive functions in children with brain-based developmental disabilities such as Attention Deficit and Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), or born with a Congenital Heart Defect (CHD).

In Canada, as many as 850,000 children under the age of 14 are living with a brain-based developmental disability, many of whom struggle with executive functions such as self-regulation, attention, impulsivity, and academic efficiency and accuracy. CHILD-BRIGHT investigators at The Hospital for Sick Children (SickKids), with industry partner Ehave, have developed Mega Team, a series of innovative cognitive rehabilitation video games to improve executive functions

The clinical trial, led by Dr. Jennifer Crosbie, Associate Scientist in the SickKids Research Institute and Principal Investigator of the project within the CHILD-BRIGHT Network, will enroll 460 children between the ages of 6 and 12 with ADHD, ASD or CHD. Children will play a series of games that target response inhibition time and working memory. Via in-clinic assessments at the start and end of the trial, and again 3 months later, the research team will measure improvements in executive functions, attention and self-regulation.

“Currently, cognitive rehabilitation interventions geared to improving cognitive deficits associated with neurodevelopmental disorders place high demands on families for professional supervision, are expensive, and have minimal established impact on behavioural regulation,” says Dr. Crosbie. “Our Mega Team game is innovative because it is a non-pharmacological intervention that is carried out at home, via an online gaming platform, and that requires very little trainer supervision. Because the game’s platform is engaging, children are motivated to play.”

Industry partner Ehave developed the mental health informatics solution Ehave Connect. The Ehave Connect platform efficiently and effectively captures data from intake to assessment to diagnosis to treatment plan to outcomes. It gives mental health clinicians and researchers a complete picture of their patients using tools they already rely upon and provides access to innovative solutions such as the CHILD-BRIGHT Mega Team game. Mega Team training is tracked on the platform, and outcomes are available to the researchers to visualize the performance over time.

“We feel there is strong clinical potential for the Mega Team game in children with ADHD, ASD and CHD”, said Prateek Dwivedi, CEO of Ehave. “The trial with the CHILD-BRIGHT Network is an important step to validate the treatment impact of Mega Team with high-quality clinical rigour. It is only with this validation that clinicians, parents, and patients can feel confident in the efficacy and safety of our digital therapy as a drug-sparing or drug-reducing treatment option.”

A pilot of the Mega Team project supported by the Ontario Brain Institute (OBI) and the Province of Ontario Neurodevelopmental (POND) Network was carried out in 2017 and provided initial evidence that game-based cognitive rehabilitation may be a promising intervention for executive function deficits.

CHILD-BRIGHT Mega Team enrollment information is available at www.child-bright.ca/megateam or by contacting the project coordinator at mega.team@sickkids.ca or 416-813-8210.

Project Funding Partners

The CHILD-BRIGHT Mega Team project is funded by the CHILD-BRIGHT Network, under the Canadian Institutes of Health Research (CIHR) Strategy for Patient-Oriented Research (SPOR) initiative, with support from the SickKids Foundation. Early development work and pilot funding for the Mega Team project was funded by the Ontario Brain Institute (OBI), Province of Ontario Neurodevelopmental (POND) Network and in-kind support from industry partner Ehave. Dr. Crosbie is supported by the Susan Bradley Health Clinician Scientist Award in Child & Youth Mental Health and the O’Brien Scholar Program.

About the CHILD-BRIGHT Network

The CHILD-BRIGHT Network, headquartered at the Research Institute of the McGill University Health Centre (RI-MUHC), is an innovative pan-Canadian network that aims to improve life outcomes for children with brain-based developmental disabilities and their families. Using child- and family-focused approaches, we work to create novel interventions to optimize development, promote health outcomes, and deliver responsive and supportive services. Co-Directed by investigators at the BC Children’s Hospital and The Hospital for Sick Children (SickKids), CHILD-BRIGHT is made possible thanks to a five-year grant by the Canadian Institutes of Health Research (CIHR) under Canada’s Strategy for Patient-Oriented Research (SPOR), and 27 generous funding partners from public and private sectors across Canada. www.child-bright.ca

SUBSCRIBE TO RECEIVE NEWS AND INSIGHTS BY EMAIL

Le Réseau BRILLEnfant, réseau canadien de recherche axée sur le patient pour les enfants touchés par des troubles du développement d’origine cérébrale, et Ehave, Inc. (OTCQB: EHVVF), entreprise du domaine des soins de santé qui renforce les moyens d’action pour les soins en santé mentale grâce à des solutions numériques de nouvelle génération, ont annoncé aujourd’hui le lancement des inscriptions à l’essai clinique du projet de recherche Mega Team du Réseau BRILLEnfant. Ce projet consiste en une intervention cognitive à l’aide de jeux vidéo conçus au Canada pour améliorer les fonctions exécutives des enfants atteints de troubles du développement d’origine cérébrale tels que le trouble déficitaire de l’attention avec hyperactivité (TDAH), le trouble du spectre de l’autisme (TSA) ou la cardiopathie congénitale.

Au Canada, jusqu’à 850 000 enfants de moins de 14 ans présentent un trouble du développement d’origine cérébrale, et beaucoup d’entre eux ont des problèmes liés aux fonctions exécutives, par exemple la maîtrise de soi, l’attention, l’impulsivité, et la capacité à être efficace et précis en milieu scolaire. Les chercheurs du Réseau BRILLEnfant qui œuvrent à The Hospital for Sick Children (SickKids), en collaboration avec Ehave, partenaire de l’industrie, ont mis au point Mega Team, soit une série de jeux vidéo novateurs de réadaptation cognitive pour améliorer les fonctions exécutives.

L’essai clinique mené par Jennifer Crosbie (Ph. D.), chercheuse associée au SickKids Research Institute et chercheuse principale du projet au Réseau BRILLEnfant, fera appel à la participation de 460 enfants âgés de 6 à 12 ans atteints d’un TDAH, d’un TSA ou d’une cardiopathie congénitale. Les enfants joueront à une série de jeux qui ciblent l’inhibition de la réponse et la mémoire de travail. Grâce à des évaluations en clinique au début et à la fin de l’essai, puis 3 mois plus tard, l’équipe de recherche mesurera les améliorations des fonctions exécutives, de l’attention et de la maîtrise de soi.

« Les interventions de réadaptation cognitive qui visent à améliorer les déficits cognitifs associés aux troubles neurodéveloppementaux sont actuellement très exigeantes pour les familles en raison de la supervision professionnelle nécessaire, des coûts élevés, et selon les données, elles ont un impact minime sur la régulation des comportements », explique Jennifer Crosbie. « Notre jeu Mega Team est novateur, car il s’agit d’une intervention non pharmacologique qui se pratique à domicile grâce à une plateforme de jeux en ligne, et très peu de formation pour la supervision est nécessaire. Comme la plateforme est conviviale, les enfants sont motivés à jouer. »

Ehave, partenaire de l’industrie, a développé une solution informatique en santé mentale, soit Ehave Connect. La plateforme Ehave Connect permet de saisir efficacement les données de la prise en charge aux évaluations, au diagnostic, au plan de traitement, et jusqu’aux résultats des traitements. Les cliniciens et les chercheurs en santé mentale peuvent ainsi obtenir un portrait complet de leurs patients en utilisant des outils sur lesquels ils s’appuient déjà, et la plateforme leur donne aussi accès à des solutions novatrices, comme au jeu Mega Team du Réseau BRILLEnfant. Les entraînements au jeu Mega Team sont consignés sur la plateforme, et les chercheurs peuvent ainsi voir les résultats et visualiser l’évolution de la performance au fil du temps.

« Nous pensons que le jeu Mega Team a un fort potentiel clinique auprès des enfants atteints d’un TDAH, d’un TSA ou d’une cardiopathie congénitale », explique Prateek Dwivedi, directeur général d’Ehave. « L’essai clinique en collaboration avec le Réseau BRILLEnfant est une étape importante pour valider avec grande rigueur les effets du traitement à l’aide de Mega Team. C’est uniquement grâce à cette validation que les cliniciens, les parents et les patients pourront être assurés de l’efficacité et de l’innocuité de notre thérapie numérique comme option de traitement pour réduire ou éliminer la prise de médicaments. »

En 2017, le projet Mega Team a été mis à l’essai par l’Institut ontarien du cerveau (IOC) et le Province of Ontario Neurodevelopmental Disorders (POND) Network, et les données recueillies ont révélé que la réadaptation cognitive à l’aide de jeux vidéo peut être une intervention prometteuse pour les troubles des fonctions exécutives.

Pour obtenir des renseignements sur l’inscription à l’essai clinique Mega Team du Réseau BRILLEnfant, visitez le site www.brillenfant.ca/megateam ou communiquez avec la coordonnatrice du projet à l’adresse mega.team@sickkids.ca ou par téléphone au 416 813-8210.

Ehave, Inc. (OTCQB: EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers.

Christine Marcotte
Communications Manager
CHILD-BRIGHT Network
christine.marcotte@child-bright.ca
(514) 412-4400 ext. 23928

Prateek Dwivedi
CEO, Ehave
media@ehave.com
(905) 362-1499

David Kugelman
dk@atlcp.com
(866) 692-6847

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.